Intuitive Surgical reports 22 percent growth and Intuitive Surgical stock trades at EUR 393.60

Published on 10/23/2026 at 11:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue rose 22 percent to USD 3.05 billion in Q3 2026. Intuitive Surgical stock costs EUR 393.60 on October 23, 2026 in trading.

Growth and the next reporting date

Third-quarter revenue rose 22 percent to USD 3.05 billion on October 20, 2026.
Intuitive Surgical placed 546 da Vinci systems in the third quarter of 2026.
Intuitive Surgical stock trades at EUR 393.60 at 11:30 a.m. CEST at Lang & Schwarz on October 23, 2026.
The next quarterly reporting date is tentatively January 26, 2027.

Modernes Architektur-Rendering eines Glas-Bürogebäudes mit Wasserbecken bei Sonnenuntergang — Architektur-Render eines Medizintechnik-Firmensitzes repräsentiert Intuitive Surgical Inc. (US46120E6023) mit gläserner Fassade bei Sonnenuntergang, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) was trading at EUR 393.60 at Lang & Schwarz at 11:30 a.m. CEST on October 23, 2026. The company reported third-quarter 2026 revenue of USD 3.05 billion, up 22 percent from the third quarter of 2025, according to Intuitive Surgical on October 20, 2026.

Revenue growth meets a legal charge

The quarterly result combined strong operating growth with a substantial one-time legal expense. GAAP net income attributable to Intuitive Surgical fell to USD 522.8 million, or USD 1.49 per diluted share, from USD 704.4 million, or USD 1.95, in the prior-year quarter. The result included a USD 450.0 million pre-tax antitrust litigation charge.

Adjusted performance was stronger. Intuitive Surgical reported non-GAAP net income of USD 1.05 billion, or USD 3.00 per diluted share, compared with USD 867.2 million, or USD 2.40, in the third quarter of 2025. Morningstar reported that adjusted earnings exceeded the USD 2.65 consensus estimate, while revenue topped the USD 2.91 billion estimate.

What does the outlook mean?

Management narrowed its full-year 2026 da Vinci procedure-growth outlook to 14 percent to 15 percent and expects results near the midpoint. It also forecast a non-GAAP gross-profit margin of 68.7 percent to 69.3 percent, including a 0.9 percentage-point tariff impact.

Procedure volume remains the main operating support. Da Vinci and Ion procedures grew 15 percent in the third quarter, while the company placed 546 da Vinci systems, up from 427 a year earlier. Instruments and accessories revenue increased 18 percent to USD 1.80 billion.

Dates for the next update

The next two relevant dates are October 20, 2026, when Intuitive Surgical held its third-quarter earnings call, and the tentative January 26, 2027, date for fourth-quarter results, as reported by Investing.com on October 21, 2026.

Stock stays tied to execution

For investors, the key tension is clear: recurring procedure and system growth is expanding the business, while pricing actions, tariffs and litigation costs affect near-term earnings quality. Intuitive Surgical identifies Nasdaq as its primary listing and operates in medical instruments and supplies.

Intuitive Surgical stock was trading at EUR 393.60 at Lang & Schwarz on October 23, 2026 at 11:30 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.